Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05920863RecruitingPhase 2
Lenvatinib, immunotherapy, plus liver artery treatment before surgery
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hangzhou, ZhejiangAges 18–75 - NCT06820255RecruitingPhase 4
DNA repair and platinum chemo for advanced bladder cancer
This trial tests how well platinum-based chemotherapy works in people with advanced bladder cancer that has certain DNA repair gene changes. It aims to see if these genetic markers can predict who benefits most from treatment.
RomeAges 18 years+ - NCT07409103RecruitingPhase 2
Testing ELV001 for active rheumatoid arthritis
This study tests a new medication, ELV001, for people with active rheumatoid arthritis who haven't improved enough with methotrexate and a TNF inhibitor. The goal is to see if different doses of ELV001 are safe and can help reduce joint pain and swelling.
Gilbert, ArizonaAges 18–75 - NCT05974358Recruiting
Compare two bowel-connection methods to prevent Crohn’s flare-ups
This trial tests whether a specific type of bowel connection during Crohn’s surgery can lower the chances that the disease comes back. It may help people having their first ileocolonic (small-to-large bowel) surgery for certain Crohn’s complications.
BesançonAges 18–75 - NCT07398170Recruiting
Searching for tumor cells in fluid for recurrent meningioma
This study looks for tumor cells in your blood or spinal fluid to see if they can help track aggressive meningiomas that have come back. It may help doctors understand your cancer better and guide future treatments.
Montpellier, FranceAges 18 years+ - NCT07398326RecruitingPhase 2
Drug combo for advanced colorectal cancer that hasn't spread to the liver
This trial tests a combination of two drugs (anlotinib and sintilimab) as a first treatment for people with advanced colorectal cancer that has spread to places other than the liver, who do not want chemotherapy. The goal is to see if this targeted therapy can help control the cancer.
ShanghaiAges 18 years+ - NCT06456515Recruiting
Regorafenib, sintilimab, and electroacupuncture for advanced colorectal cancer
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
ChangzhouAges 18–75 - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Jonesboro, ArkansasAges 18 years+ - NCT07393555RecruitingPhase 2
Treatment for advanced lung cancer after targeted therapy and chemotherapy
This study tests a new treatment for advanced non-small cell lung cancer that has stopped responding to targeted therapy and chemotherapy. The goal is to find a treatment that works better for people whose cancer has certain genetic changes.
Berkeley, CaliforniaAges 18 years+ - NCT07395505Enrolling by invitation
Surgery for advanced rectal or anal cancer
This trial studies the results of a major surgery called pelvic exenteration for patients with advanced rectal or anal cancer that has spread to nearby tissues or bones but not to distant organs. The goal is to see how well the surgery works and how patients recover afterward.
TaoyuanAges 20 years+ - NCT07392957RecruitingPhase 1/Phase 2
Testing CTX-009 with CTX-471 for recurrent glioblastoma
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
St Louis, MissouriAges 18 years+ - NCT07392658RecruitingPhase 2
Amivantamab plus chemo for EGFR-mutated lung cancer
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
Roma, Roma (RM)Ages 18–99 - NCT05417932RecruitingPhase 1/Phase 2
Cell therapy for hepatitis B–related liver cancer
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
New York, New YorkAges 18–70 - NCT06831773Recruiting
Carbon ion radiation for high-grade brain tumors
This trial tests a precise type of radiation called carbon ion radiotherapy for people with aggressive brain tumors (high-grade gliomas). It aims to see if this treatment is safe and effective for patients who have not had radiation to the head before.
Wuwei, GansuAges 14–80 - NCT04095572RecruitingPhase 4
Prevention options for recurring bladder infections in women
This trial studies different ways to prevent repeated bladder (urinary tract) infections in women. It may help people who keep getting these infections by testing safer or more effective prevention strategies.
BaselAges 18–70 - NCT06725433Recruiting
Nissen vs Dor repair for hiatal hernia
This trial compares two types of hiatal hernia repair: Nissen and Dor fundoplication. It aims to see which one works better for patients having keyhole surgery for a large hiatal hernia.
KuopioAges 18 years+ - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT07371403Recruiting
Car-t cell therapy for relapsed or refractory acute lymphoblastic leukemia
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
AmmanAges 1 year+ - NCT07371585RecruitingPhase 2
Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
VillejuifAges 18 years+ - NCT07377747Recruiting
Study of treatment for recurrent retroperitoneal liposarcoma
This study looks at how well standard treatments work for people whose liposarcoma has come back in the same area. It helps doctors understand best ways to manage this rare cancer.
Atlanta, GeorgiaAges 18 years+ - NCT07362134Enrolling by invitation
Pulsed-field ablation for recurrent atypical atrial flutter
This study tests a new type of energy called pulsed-field ablation (PFA) to treat a specific kind of irregular heartbeat called atypical atrial flutter that keeps coming back after a prior ablation. It aims to see if this approach can safely stop the abnormal rhythm.
TaipeiAges 18–80 - NCT07363252Recruiting
Study of why lung cancer returns after osimertinib treatment
This study looks at why lung cancer returns in people who took the targeted pill osimertinib after surgery. If your cancer has come back, researchers will test your tumor or blood sample to understand how the cancer changed.
Bari, BAAges 18 years+ - NCT07359404Enrolling by invitationPhase 2
Sacituzumab Govitecan plus Bevacizumab for metastatic TNBC
This trial tests a combination of two drugs, Sacituzumab Govitecan and Bevacizumab, for people with advanced triple-negative breast cancer that has already been treated. The goal is to see if the combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07357311Recruiting
Screening for Fear of Cancer Recurrence
This study aims to help people with breast or lung cancer who worry about their cancer coming back. You will answer questionnaires about your fears, so the care team can better support you.
ParisAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.